August 29, 2012
Is your memory loss a sign of aging? Or something else…Research for People with Mild Cognitive Impairment and Early Alzheimer’s
NeuroTrials Research specializes in clinical trials for a variety of neurological and sleep disorders. Frequent research includes Alzheimer’s disease and other forms of cognitive impairment.
We are currently enrolling for a clinical trial for individuals with Mild Cognitive Impairment or early Alzheimer’s disease – details are described below. If you or someone you know may qualify, please contact us at (404) 851-9934. Help us research solutions for Alzheimer’s!
Mild Cognitive Impairment or Mild Alzheimer’s Sleep Research Study
This is a 7 week study to examine an investigational cognitive enhancement drug and its effect on sleep quality in volunteers with mild cognitive impairment or early Alzheimer’s disease. Compensation is available for the patient and the study partner.
- Age 50-85
- Have Mild Cognitive Impairment or early Alzheimer’s disease
- No other major neurological disorders or history of stroke
- Good general health with no unstable conditions
- Patient must have a “study partner”, which may be a caregiver, family member, or friend who visits with them regularly. The study partner must be capable and willing to accompany the patient to the first visit and additional visits as needed.
To learn more about this study, visit our study page.
We also have new research studies opening up throughout the year. For more information about this study, or to be included in our patient database for future studies, please contact us at (404) 851-9934, or visit us at www.neurotrials.com.
August 27, 2012
NeuroTrials Research & Atlanta School of Sleep Medicine CEO Dr. Russell Rosenberg joined the NPR Morning Edition show today to discuss sleepwalkers. An excerpt from the interview is below:
Though a sleepwalker’s brain might be partially awake, most sleepwalkers have no memory of their episodes, and that’s a key feature, says Russell Rosenberg, chairman of the National Sleep Foundation and CEO of Neural Trials Research in Atlanta. Some research suggests that the sleepwalker’s frontal cortex — the brain’s center for decision-making, judgment and short-term memory — is not fully online during sleepwalking.
For the full transcript of the interview or to listen online, click here.
August 1, 2012
Researchers at the Wayne State University School of Medicine, working with colleagues in Canada, have found that one or more substances produced by a type of immune cell in people with multiple sclerosis (MS) may play a role in the disease’s progression. The finding could lead to new targeted therapies for MS treatment.
B cells, said Robert Lisak, M.D., professor of neurology at Wayne State and lead author of the study, are a subset of lymphocytes (a type of circulating white blood cell) that mature to become plasma cells and produce proteins that serve as antibodies.
In patients with MS, the B cells seem to attack the brain and spinal cord. Researchers believe that there might be substances produced in the nervous system and the covering of the brain and spinal cord that attract the cells. Once the B cells are inside the central nervous system or brain, the cells secrete substances that damage the cells that produce protections.
“We think this is a very significant finding, particularly for the damage to the cerebral cortex seen in patients with MS, because those areas seem to be damaged by material spreading into the brain from the meninges, which are rich in B cells adjacent to the areas of brain damage,” Lisak said.
Do you have MS? NeuroTrials Research is conducting a research study to determine the efficacy of an investigational drug. Qualified participants receive all study-related exams and study drug at no cost. Compensation is available for time and travel. For more information, visit the study page or call us at 404-538-9284.